Shelton biotech Intensity Therapeutics paused its Phase 3 cancer trial after running low on cash. The company needs $30M to finish testing INT230-6, an injectable drug that attacks tumors directly.
COVID-era financial assistance for ObamaCare health plans are all but guaranteed to lapse at the end of the year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback